Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC8517	BS194 Featured	BS-194 is a selective and potent CDK inhibitor, which inhibits CDK2, CDK1, CDK5, CDK7, and CDK9 with IC50 values of 3, 30, 30, 250, and 90 nM respectively.
DC7378	BSI-201	BSI-201 (Iniparib; NSC-746045) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC).
DC26026	Btk inhibitor 2	Btk inhibitor 2 is a Bruton's tyrosine kinase (BTK) inhibitor extracted from patent US 20170224688 A1.
DC12432	BTK inhibitor 4b	BTK inhibitor 4b is a potent, highly selective inhibitors of BTK with IC50 of 4.2 and 0.9 nM against activated and unactivated BTK, respectively.
DC11065	BTK PROTAC 10	BTK PROTAC 10 is a novel potent PROTAC for BTK with DC50 of 1.1 nM in cultured Ramos cells.
DC11064	BTK PROTAC 9	BTK PROTAC 9 is a novel potent PROTAC for BTK with DC50 of 5.9 nM in cultured Ramos cells, requires simultaneous engagement of BTK and CRBN to effectively degrade BTK.
DC11431	BTK-030	BTK-030 is a novel BTK inhibitor.
DC23870	BTK-IN-23	BTK-IN-23 is a highly potent and selective Btk inhibitor with IC50 of 3 nM.
DC23413	BTRX335140 Featured	BTRX-335140 (CYM-53093, BTRX335140, CYM53093) is a potent, selective, orally active κ opioid receptor (KOR) antagonist with IC50 of 0.8 nM.
DC12456	BTT-266 Featured	BTT-266 (BTT266) is a voltage-gated CaV2.2 calcium channel inhibitor that disrupts the CaVα·CaVβ3 protein-protein interaction, directly binds to CaVβ3 with Kd of 3.6 uM.
DC12457	BTT-369	BTT-369 (BTT369) is a voltage-gated CaV2.2 calcium channel inhibitor that disrupts the CaVα·CaVβ3 protein-protein interaction with Ki of 2.0 uM in FP assays.
DC11252	BTX161	BTX161 is a thalidomide analog that mediates degradation of CKIα better than lenalidomide in human AML cells and activates DDR and p53, while stabilizing the p53 antagonist MDM2.
DC23703	BTYNB Featured	BTYNB is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA with IC50 of 5 uM.
DCAPI1392	BTZ043 racemate Featured	BTZ043 racemate is a decaprenylphosphoryl-β-D-ribose 2-epimerase (DprE1) inhibitor acting as a new antimycobacterial agent that kill Mycobacterium tuberculosis.
DC22041	BTZO-1 Featured	BTZO-1 is a cardioprotective agent and Macrophage migration inhibitory factor (MIF) activator, binds to MIF with Kd of 68.6 nM, regulates ARE-mediated gene expression.
DC22042	BTZO-15	BTZO-15 is an active BTZO-1 derivative for ARE-activation with a favorable ADME-Tox profile, induces expression of heme oxygenase-1 (HO-1) and inhibits NO-induced cell death in IEC-18 cells.
DC22043	BTZO-2	BTZO-2 is an active BTZO-1 derivative, an antioxidant response element-activator, provides protection against lethal endotoxic shock in mice..
DC10945	BU09059	BU09059 is a potent, selective, short-acting kappa-opioid receptor antagonist with Ki of 1.72 nM, displays 15- and 616-fold selectivity over μ- and δ-receptors respectively.
DC6501	Bufalin Featured	Bufalin inhibits steroid receptor coactivator 1 (SRC-1) and SRC-3 at doses as low as 5 nM, promotes the degradation of SRC-3 protein, and inhibits cancer cell growth both in vitro and in vivo.
DC9360	Buparvaquone	Buparvaquone(Butalex) is a hydroxynaphthoquinone antiprotozoal drug related to parvaquone and atovaquone; it is a promising compound for the therapy and prophylaxis of all forms of theileriosis.
DC22437	Burimamide oxalate	Burimamide oxalate is a potent dual H3/H2 receptor antagonist with Ki of 0.07 and 7.8 uM, respectively.
DC20059	Burixafor hydrobromide (TG-0054 hydrobromide)	Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent antagonist of CXCR4 and a well water soluble anti-angiogenic drug that is of potential value in treating choroid neovascularization. Burixafor hydrobromide (TG-0054 hydrobr
DC8278	BVT-14225 Featured	BVT 14225 is a new selective 11b-HSD1 inhibitor, it belongs to a class of arylsulfonamidothiazoles with in vitro and in vivo antidiabetic effects
DC21685	BVT-948 Featured	BVT-948 (SPS8I-3) is a noncompetitive, cell-permeable inhibitor of protein tyrosine phosphatases (PTPs) with IC50 of 0.09-1.7 uM. Results show that the effect of BVT948 (BVT.948) is to strengthen the insulin signal and has no effects on the duration of th
DC20852	BX-320	BX-320 is a potent, selective and ATP-competitive inhibitor of PDK1 with IC50 of 30 nM, >20-fold selectivity over PKA.
DC22424	BX-667	BX-667 is a potent P2Y12 receptor antagonist that blocks ADP-induced platelet aggregation in human, dog and rat blood (IC50=97, 317 and 3000 nM respectively).
DC11219	BXI-72 Featured	BXI-72 (NSC334072) is a potent, selective small molecule Bcl-XL inhibitor that targets the BH3 domain of Bcl-XL (Kd=0.9 nM).
DC11058	BYK191023	BYK191023 (BYK-191023) is a potent, highly selective inhibitor of inducible nitric-oxide synthase (iNOS) with IC50 of 86 nM, >20-fold selectivity over nNOS and eNOS (IC50=17 and 162 uM).
DC11059	BYK191023 dihydrochloride	BYK191023 dihydrochloride (BYK-191023) is a potent, highly selective inhibitor of inducible nitric-oxide synthase (iNOS) with IC50 of 86 nM, >20-fold selectivity over nNOS and eNOS (IC50=17 and 162 uM).
DC20853	BZ-194	BZ-194 is a small molecule inhibitor of NAADP action that inhibit NAADP-mediated Ca2+ signaling in T cells, neither interferes with Ca2+ mobilization by IP3 or cyclic ADP-ribose nor with capacitative Ca2+ entry.

Novel inhibitors

Customized Consultation X

Your information is safe with us. * Required Fields.